Explore Products
Tumor Cell Lines

KARPAS 299

  • 313
A human T cell lymphoma cell line established from the peripheral blood of a 25-year-old man with T cell non-Hodgkin′s lymphoma in 1986.
Request Your Custom Quote Today

Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.

Get a Quote
  • High Purity Levels
  • Precision and Reliability
  • Customization Options
Product Code

KARPAS-299; Karpas 299; KARPAS 299; Karpas299; KARPAS299; K299

Species

Human

Cat.No

ABC-TC5559

Product Category Tumor Cell Lines
Size/Quantity

1 vial

Cell Type

Lymphoblastoid

Shipping Info

Dry ice

Growth Conditions

37 ℃, 5% CO2

Source Organ

Lymphoma

Disease

Anaplastic Large Cell Lymphoma

Storage

Liquid Nitrogen

Product Type

Human Lymphoma Cell Lines

Description

KARPAS 299KARPAS 299 is a human T-cell lymphoma cell line established in 1986 from the peripheral blood of a 25-year-old Caucasian male diagnosed with T-cell non-Hodgkin’s lymphoma, now classified as CD30+ anaplastic large cell lymphoma (ALCL) . The cells exhibit a lymphoblastoid morphology and grow in suspension as single cells or small clusters, with a doubling time of approximately 30 hours. Cytogenetic analysis reveals a hypodiploid karyotype, featuring the hallmark t(2;5)(p23;q35) translocation, which generates the oncogenic NPM-ALK fusion gene. KARPAS 299 expresses a range of T-cell surface markers (CD2, CD3, CD4, CD5, and CD7), along with high levels of CD30 (Ki-1 antigen) and ALK protein. The cell line is tumorigenic in immunodeficient mice and reliably forms xenografts tumors, making it a critical model for studying ALCL biology and CD30-targeted therapies.

View Product Image

Citation

When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).

Application

  • KARPAS 299 is a critical tool in lymphoma research, widely used to explore the molecular mechanisms of the t(2;5) translocation and the oncogenic activity of the NPM-ALK fusion protein. It is particularly valuable for characterizing CD30-positive large cell lymphomas and dissecting the signaling pathways involved in ALCL pathogenesis. This cell line supports the development and testing of targeted therapies, especially those aimed at ALK and CD30, such as monoclonal antibodies and small-molecule inhibitors. Its utility in xenograft models further enhances its relevance in translational research and therapeutic discovery for aggressive T-cell lymphomas.

Inquiring KARPAS 299

We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time? Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
High Viability
To succeed in cell culture
Precision and Reliability
To support a consistent result
Customization Options
Tailed to your research

Tags

AcceGen Scroll Top Button